# The Dose That Stopped Helping

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/the-dose-that-stopped-helping

> ACHIEVE-5 tested three doses of oral orforglipron on top of insulin in 546 adults with long-standing type 2 diabetes. Blood sugar improved at every dose, and the top dose was not better than the middle one.

## Key points

- HbA1c: 12 mg −1.88%, 36 mg −1.82%. Tripling the dose bought nothing on blood sugar.
- But weight kept falling with dose (2.6% → 4.8% → 5.4%). Two endpoints, two ceilings.
- Median 14.6 years of diabetes, everyone on insulin. The hard end of the disease.
- The small weight number is expected: insulin causes weight gain, and placebo GAINED 0.2%.
- 92.9% completed a 40-week trial.
- No cardiovascular or kidney outcomes.

ACHIEVE-5 tested three doses of oral orforglipron on top of insulin in 546 adults with long-standing type 2 diabetes. Blood sugar improved at every dose, but **the top dose was not better than the middle one**.[1] Tripling from 12 mg to 36 mg bought nothing on HbA1c, which is not what the word “higher” leads people to expect. Orforglipron’s [trial against dapagliflozin](https://glpwatchdog.org/research/the-top-dose-keeps-not-being-worth-it) found the same pattern at 36 mg.

## The middle row

*ACHIEVE-5 at 40 weeks, added to titrated insulin glargine.[1]*

| Dose | HbA1c change | vs placebo (95% CI) | Weight change |
| --- | --- | --- | --- |
| Orforglipron 3 mg | −1.58% | −0.78% (−1.02 to −0.55) | −2.6% |
| **Orforglipron 12 mg** | **−1.88%** | **−1.08% (−1.33 to −0.83)** | −4.8% |
| Orforglipron 36 mg | −1.82% | −1.03% (−1.28 to −0.77) | **−5.4%** |
| Placebo | −0.79% | — | +0.2% |

Every dose beat placebo at P<0.001, and the confidence intervals for 12 mg and 36 mg overlap almost entirely. On blood sugar, the effect has reached a ceiling somewhere between 3 and 12 mg, and going higher does not move it.

> The two endpoints stop responding at different doses.

Weight kept falling as the dose rose: 2.6%, then 4.8%, then 5.4%. So the same drug shows a plateau on one outcome and a continuing gradient on another. Anyone reasoning that a higher dose is simply a stronger version of the same thing has the wrong model, and the dose that is right depends on which problem is being treated.

## Who was in this trial

> **Median duration of diabetes: 14.6 years. Everyone was on insulin. Mean HbA1c 8.50%.** This is the difficult end of type 2 diabetes. These are people whose pancreatic function has been declining for over a decade and who already need injected insulin to manage it.

That context changes how the numbers should be read. We recently covered a trial of a different drug in people managing diabetes with *diet and exercise alone*, a median of 2.5 years from diagnosis, which posted an HbA1c reduction of 1.94% ([retatrutide’s phase 3](https://glpwatchdog.org/research/retatrutide-phase-3-and-the-gray-market)). The figures look comparable. The populations are not remotely comparable, and we are not setting them against each other.

Achieving nearly two points of HbA1c reduction alongside titrated insulin, fourteen years in, is a harder thing than achieving the same reduction in someone recently diagnosed and taking nothing. Not all of that fall is the drug’s. The placebo group, whose insulin was titrated too, fell 0.79 points, so the drug’s own share was 1.08.[1]

## Why the weight number looks small

A 5.4% reduction at the top dose is far below what orforglipron produced in obesity trials, and that is expected rather than disappointing. Insulin causes weight gain, and the placebo group here *gained* 0.2% while having their insulin titrated upward. The drug was working against that.

Reading this figure against an obesity trial would be a category error of the kind this register documents regularly. Different population, different concurrent treatment, different question. Orforglipron’s obesity results are covered in [ATTAIN-2](https://glpwatchdog.org/research/an-oral-pill-in-a-diabetes-population).

## What it is good for

- **It answers a real clinical question.** Someone on insulin whose blood sugar is still too high has limited options, and adding an oral drug rather than more injections is a meaningful one.
- **Completion was high** (507 of 546, or 92.9%), which is a good sign for tolerability in a 40-week trial.
- **The ceiling is practically useful.** If 12 mg does what 36 mg does for blood sugar, the higher dose earns its place only through the extra weight effect, which is a different trade to weigh.
- **Forty weeks is short** for a condition managed over decades, and this trial reports no cardiovascular or kidney outcomes.

Whether a higher dose costs more is a separate question from whether it works better, and for cash buyers of compounded semaglutide or tirzepatide (not orforglipron, which is not compounded) the answer depends on the seller. [Center for Medical Weight Loss (CMWL)](https://glpwatchdog.org/reviews/center-for-medical-weight-loss), [LevelsRx](https://glpwatchdog.org/reviews/levelsrx) and [Luci](https://glpwatchdog.org/reviews/luci) charge one price at every dose. So does [Better U Care](https://glpwatchdog.org/reviews/better-u-care), which also handles brand-name prescriptions as a separate appointment.

Some flat-priced sellers attach conditions. [tru Weight Loss](https://glpwatchdog.org/reviews/tru-weight-loss) and [Aspen](https://glpwatchdog.org/reviews/aspen-health) both require a three-month commitment, and tru includes lab work in its fee. [Loop Health](https://glpwatchdog.org/reviews/loop-health) sells only microdosed GLP-1s, while [Superior Remedies](https://glpwatchdog.org/reviews/superior-remedies) offers a microdose protocol beside its standard plans. [Rese Wellness](https://glpwatchdog.org/reviews/rese-wellness) holds its price at every dose too, but every patient starts with a three-month program paid in a single charge; after that, months are bought one at a time with no subscription. With pricing like this, a step up costs nothing extra, so the decision comes back to the trade this trial describes.

## Frequently asked questions

### Does orforglipron work added to insulin?

Yes. In 546 adults with long-standing type 2 diabetes on insulin glargine, HbA1c fell 1.58% to 1.88% depending on dose against 0.79% on placebo, with every dose superior at P<0.001.

### Is the highest dose the best one?

Not for blood sugar. The 36 mg dose produced 1.82% against 12 mg's 1.88%, with overlapping confidence intervals. The effect had reached a ceiling. Weight loss did keep increasing with dose, from 4.8% to 5.4%.

### Why is the weight loss so much smaller than in obesity trials?

Because everyone was on insulin, which causes weight gain, and their insulin was being titrated upward during the trial. The placebo group gained 0.2%. The drug was working against that, which an obesity trial is not.

### How difficult was this population?

Median diabetes duration was 14.6 years, everyone was on insulin, and mean HbA1c was 8.50%. This is the end of the disease where treatments generally perform worst.

### What does it not tell us?

Anything about cardiovascular or kidney outcomes, or about durability past 40 weeks in a condition managed across decades.

## References

1. Giorgino F, D'Souza S, Ludwig L, et al. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. JAMA. 2026. PMID: 42251769. https://pubmed.ncbi.nlm.nih.gov/42251769/

---

Cite as: GLP Watchdog, Nora Bissett, "The Dose That Stopped Helping", published 2026-08-20, updated 2026-10-30. https://glpwatchdog.org/research/the-dose-that-stopped-helping

Canonical HTML page: https://glpwatchdog.org/research/the-dose-that-stopped-helping

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
